ForSight Robotics has secured $125 million in Series B funding to support the continued expansion of its robotic ophthalmic surgery platform: ORYOM.
First, a ForSight refresh.
The Israeli surgical robotics company has developed its flagship technology as the world’s first robotic surgery platform for cataracts and widespread ocular diseases.
How it’s done this: Through a series of funding rounds ranging from $10 million to (most recently) $55 million.
Before we get into this platform, talk about this latest financing.
The funding round was led by Eclipse, an early-stage venture firm, and included an undisclosed strategic investor as well as the following existing investors:
- Frederic Moll, MD (dubbed “the father of robotic surgery”)
- Adani Group
- Reiya Ventures
The company’s new total funding now clocks in at $195 million.
And what will it be used for, specifically?
The platform’s “next growth phase,” which will include launching first-in-human (FIH) clinical trials later this year.
Alrighty, now tell me more about ORYOM.
Its official name: the ORYOM Surgical Robotics Platform.
- Fun fact: “ORYOM” translates to “daylight” in Hebrew
What it is: The world’s first hybrid intraocular robotic ophthalmic platform designed to provide enhanced surgical precision and high-quality treatment for patients, as well as deliver advanced capabilities beyond standard cataract surgery, including:
- High-volume procedures
- Increased multitasking levels
- Advanced high-precision procedures
- Consistent and monotonous flow
Talk about its design.
This platform is equipped with three integral components that enable such precise delivery.
- Robotic hand
- Gives superior dexterity and maneuverability
- Features a miniature 14°-of-freedom microsurgical robot for carrying out delicate tasks
- Includes a hybrid kinematic structure that reaches any location within the human eye
- Advanced visualization
- Offers stereoscopic imaging technologies for:
- Surgical planning
- Real-time image guidance
- Visualization
- Offers stereoscopic imaging technologies for:
- Advanced data analytics
- Offers state-of-the-art computing methods via machine learning for continuous surgical technique advancement
And how does it operate?
The platform utilizes artificial intelligence (AI)-based algorithms along with advanced computer vision and micromechanics.
Plus: Circling back to that robotic hand, its ability to reach anywhere within the human eye means surgeons can navigate complex angles, accessing both the anterior and posterior segments.
Which means …
The ORYOM could be relied on to perform glaucoma and retinal surgical treatment.
Nice! Now, has this been tested out yet?
Indeed it has. To date, ForSight noted that over 24 ophthalmic surgeons have successfully used the platform to complete “hundreds of procedures on animal eye models.”
In fact, the ORYOM made its debut back in 2024 during the American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting.
- Check out those details here—and watch a video of the platform in action.
And about those future clinical trial plans …
The company’s robotic cataract surgery clinical trials are expected to kick off in the coming year as it strives to tap into an increasingly in-demand and declining workforce of ophthalmologists and cataract surgeons.
Keep your eyes out for more developments with this in the coming months!